Physician profile
Erum Karafa
NPI 1437645736
$1,576.55
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,144 · 2022: $203 · 2023: $170 · 2024: $59.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $926.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $190.44 | 2021-2024 | Brilinta, Airsupra |
| Novo Nordisk INC | $126.29 | 2022-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $78.21 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.41 | 2022 | |
| Pfizer INC. | $38.77 | 2023-2024 | |
| Lucid Diagnostics INC. | $37.35 | 2022-2023 | |
| Astellas Pharma US INC | $34.11 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $18.79 | 2022 | |
| Indivior INC. | $18.05 | 2021 | |
| Esperion Therapeutics, INC. | $16.56 | 2021 | |
| Intra-Sana Laboratories | $16.39 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Sanofi Pasteur INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erum Karafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.